|2.11||+0.0900||+4.46%||Vol 377.54K||1Y Perf 80.36%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||-0.04 -1.90%|
|Target Price||12.63||Analyst Rating||Strong Buy 1.00|
|Potential %||498.58||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/50/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/98/30||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/97/80||Income Ranking||— -|
|Price Range Ratio 52W %||58.51||Earnings Rating||Neutral|
|Market Cap||162.95M||Earnings Date||8th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||413.64K|
|Avg. Monthly Volume||551.50K|
|Avg. Quarterly Volume||1.01M|
Applied Therapeutics Inc. (NASDAQ: APLT) stock closed at 2.11 per share at the end of the most recent trading day (a 4.46% change compared to the prior day closing price) with a volume of 377.54K shares and market capitalization of 162.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Applied Therapeutics Inc. CEO is Shoshana Shendelman.
The one-year performance of Applied Therapeutics Inc. stock is 80.36%, while year-to-date (YTD) performance is 177.63%. APLT stock has a five-year performance of %. Its 52-week range is between 0.7 and 3.11, which gives APLT stock a 52-week price range ratio of 58.51%
Applied Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 4.47, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -121.24%, a ROC of -186.19% and a ROE of -229.28%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Applied Therapeutics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Applied Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Applied Therapeutics Inc. is Strong Buy (1), with a target price of $12.63, which is +498.58% compared to the current price. The earnings rating for Applied Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Applied Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Applied Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.93, ATR14 : 0.22, CCI20 : -5.87, Chaikin Money Flow : -0.05, MACD : -0.10, Money Flow Index : 20.10, ROC : 3.94, RSI : 49.04, STOCH (14,3) : 57.14, STOCH RSI : 1.00, UO : 45.73, Williams %R : -42.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Applied Therapeutics Inc. in the last 12-months were: Hansard Adam (Sold 14 215 shares of value $30 334 ), Joel M. Marcus (Option Excercise at a value of $12 994), Perfetti Riccardo (Sold 16 985 shares of value $35 025 ), Real Estate Equities Inc Alexandria (Sold 575 000 shares of value $1 353 425 ), Shoshana Shendelman (Sold 131 502 shares of value $326 648 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.